Ian Sefferman is bullish on the Midwest, particularly Detroit. A native of the area, Sefferman started a Seattle-based app marketing company called MobileDevHQ that was acquired by TUNE in 2014. While Sefferman was deciding what to do next, he moved back to Detroit last year to be closer to family and learn more about the … Continue reading “Assembler Labs Aims to Get Detroit Entrepreneurs Out of Their Shells”
Category: Indiana
IPO Wave Rolls On as Five Life Science Firms Haul In $651M
A week after seven biotechs went public, setting a new record for the Nasdaq, five more life sciences companies have joined the club. The latest crop continued the positive momentum for life sciences offerings, as the group either met or exceeded their projections and raised a total of $651 million. Neon Therapeutics (NASDAQ: [[ticker:NTGN]]) was … Continue reading “IPO Wave Rolls On as Five Life Science Firms Haul In $651M”
Senators Grill HHS’s Azar on Drug Price Cuts That Have Yet to Come
When President Trump signed legislation last month allowing seriously ill patients the “right to try” unapproved drugs without FDA oversight, he voiced a bold prediction: Within two weeks, he said, drug companies would announce “voluntary massive drops in prices.” Asked for further detail, the Department of Health and Human Services (HHS) declined to elaborate on … Continue reading “Senators Grill HHS’s Azar on Drug Price Cuts That Have Yet to Come”
How the Rise of Beijing and Shanghai Tech May Impact Silicon Valley
When it comes to startup tech hubs, U.S. cities from San Francisco to Austin to Boston come first to mind. But that is starting to change, as Asian cities—particularly in China—are snapping up more tech venture capital funding and exits, according to a new report from CB Insights. Silicon Valley tech startups pulled in the … Continue reading “How the Rise of Beijing and Shanghai Tech May Impact Silicon Valley”
Stitch Fix CTO Polinsky Says Its Style Shuffle Game Makes Data Fun
When Cathy Polinsky became chief technology officer of Stitch Fix in late 2016, she knew one of the San Francisco-based company’s key challenges was continually refining its core software algorithm to make sure customers received the right tailored suggestions in their monthly wardrobe boxes. So, she made it into a game. Style Shuffle is a … Continue reading “Stitch Fix CTO Polinsky Says Its Style Shuffle Game Makes Data Fun”
Costello Raises $2.1M to Accommodate Growing Customer Demand
Costello, the Indianapolis-based software startup, this week announced that it has raised $2.1 million in seed funding. A number of local and out-of-state investors contributed to the round, including Dundee Ventures, Collina Ventures, Silicon Valley’s Social Capital, Copper Mountain Technologies CEO Irena Goloschokin, and ExactTarget co-founder Chris Baggott. Costello’s software brings artificial intelligence to the … Continue reading “Costello Raises $2.1M to Accommodate Growing Customer Demand”
Some of the Best Reads for Casual Friday: Artificial Intelligence
Fridays can be the most productive work day, as you look to shore up everything before the weekend starts. Or, maybe instead, it’s a day filled with long lunches and listless Internet surfing, as you seek out all the interesting articles you missed during the week. Fear not: Xconomy has done the work for you, … Continue reading “Some of the Best Reads for Casual Friday: Artificial Intelligence”
Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More
Biotech financing is a cyclical thing. Two years ago, the IPO window was unlatched but a number of companies ended up withdrawing their stock offerings. Others that pushed their IPOs through couldn’t sell shares at the price they wanted. This year, the IPO window is wide open. A total of 93 IPOs have priced as … Continue reading “Bio Roundup: Duchenne Data, Roche Buys Foundation, IPO Wave & More”
Intel CEO Resigns After Board Learns of His Relationship With Employee
Intel (NASDAQ: [[ticker:INTC]]) announced Thursday that CEO Brian Krzanich has resigned in the wake of the company’s recent discovery that he had been involved in a past consensual relationship with an Intel employee. The relationship violated Intel’s non-fraternization policy—the finding of an ongoing investigation by internal and external counsel, the company said in a written … Continue reading “Intel CEO Resigns After Board Learns of His Relationship With Employee”
Latticework Launches Personal Hybrid Cloud for Private Data-Sharing
Were you aghast at revelations that third-party organizations were able to capture millions of Facebook profiles from users who were unaware of the company’s privacy policy terms? If so, a Silicon Valley startup is hoping to entice you with a new option for private data storage of your personal digital life, along with private channels … Continue reading “Latticework Launches Personal Hybrid Cloud for Private Data-Sharing”
Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours
The window for biotech IPOs remains wide open and six more companies have charged through it, raising more than $568 million in the span of 24 hours. The first was Eidos Therapeutics (NASDAQ: [[ticker:EIDX]]), which raised $106 million in its stock market debut. The San Francisco company priced its IPO late Tuesday, selling 6.25 million … Continue reading “Bio IPO Madness: Six Biotech Startups Raise $568M in 24 Hours”
CrowdStrike Hauls In $200M, Reports Valuation Over $3 Billion
CrowdStrike, a Silicon Valley cybersecurity company that fends off hackers by patrolling the edge devices connected to a network, announced today it raised $200 million in a financing round that sets the company’s valuation at more than $3 billion. Sunnyvale, CA-based CrowdStrike, as an endpoint protection and response platform, uses next-generation antivirus software, scans for … Continue reading “CrowdStrike Hauls In $200M, Reports Valuation Over $3 Billion”
Biotech Beware, Your Culture Is Showing
In a recent survey of 220 scientists, 60 percent of the respondents reported having experienced harassment at a conference at some point in their careers. Even more astounding is the fact that 82 percent of those who reported harassment did not report it when it occurred. That’s why it’s easy to say, “How big of … Continue reading “Biotech Beware, Your Culture Is Showing”
Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches
Teva Pharmaceutical’s bid to add a new therapeutic application for its experimental migraine-prevention drug has faltered in a late-stage study. Israel-based Teva (NYSE: [[ticker:TEVA]]) said Friday that it is stopping a Phase 3 clinical trial testing its drug, fremanezumab, for prevention of chronic cluster headaches. According to the company, an analysis found that the study … Continue reading “Teva’s Migraine Drug Fails in Phase 3 for Chronic Cluster Headaches”
Bio Roundup: Not-BIO Party Foul, CRISPR Drama, Sickle Cell Updates
This week brought a sobering reminder of how far away we are from true gender equality in the life sciences. An industry party held during BIO’s annual meeting in Boston last week featured scantily clad women with company logos painted on their bodies—two years after the infamous party at the J.P. Morgan party in San … Continue reading “Bio Roundup: Not-BIO Party Foul, CRISPR Drama, Sickle Cell Updates”
For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs
Cassandra Trimnell has sickle cell disease. She also loves to travel. For her 30th birthday last year, she and her husband planned a trip to Indonesia, and she figured she would be fine. Growing up in Iowa, she was sick all the time, in and out of hospitals with severe pain episodes, or “crises,” and … Continue reading “For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs”
16 Tech’s 60-Acre Innovation Community Coming Soon to Downtown Indy
In case you’ve missed it, the Indianapolis tech community is booming. Indy is one of 20 finalists for Amazon’s second American headquarters, Salesforce’s 2015 acquisition of homegrown startup ExactTarget continues to have ripple effects as former execs seed new startups, talent is flocking to the Midwest after being priced out of the coasts, and out-of-state … Continue reading “16 Tech’s 60-Acre Innovation Community Coming Soon to Downtown Indy”
Zurex Pharma Raises $9M to Fight Hospital-Acquired Infections
Zurex Pharma, a Middleton, WI-based company developing antimicrobial products for preventing infections acquired in hospitals, clinics, and home care settings, says it has raised $9 million in new funding. Zurex says it plans to use some of the proceeds from the investment to support the development of its lead product candidate, a pre-surgical skin preparation … Continue reading “Zurex Pharma Raises $9M to Fight Hospital-Acquired Infections”
New York Fashion Tech Lab Connects Retail to Crucial Innovations
Amazon is fundamentally disrupting how and where we shop, but in-store retail still has life in it. The Seattle e-commerce giant is “a hefty competitor, but that doesn’t mean brands and retailers don’t have the ability to fight back,” says Kay Koplovitz, co-founder and managing partner of Springboard Growth Capital in New York. In fact, … Continue reading “New York Fashion Tech Lab Connects Retail to Crucial Innovations”
Allergan’s Migraine-Reducing Pill Hits Study Goals, Heads to Phase 3
An experimental Allergan pill meant to help reduce the frequency of migraines met the main goals of a key study, bolstering its chances of eventually being in the mix with a new wave of injectable migraine-preventing therapies. The results announced Monday for the Allergan (NYSE: [[ticker:AGN]]) drug, atogepant, come a month after Amgen (NASDAQ: [[ticker:AMGN]]) … Continue reading “Allergan’s Migraine-Reducing Pill Hits Study Goals, Heads to Phase 3”
Data Centers on Wheels: How Intel Plans to Capitalize on Mobility
Intel sealed its commitment to become a player in the burgeoning autonomous vehicle industry when it bought computer vision company Mobileye for more than $15 billion in 2017. The venerable Santa Clara, CA-based chipmaker is betting that its data analytics and connectivity chops—as well as its semiconductors—combined with Mobileye’s computer vision and mapping functions, will … Continue reading “Data Centers on Wheels: How Intel Plans to Capitalize on Mobility”
Bio Roundup: Wrapping ASCO, Dreaming IPO, Rebooting Axovant & More
Most of the cancer news this week happened at the massive ASCO meeting in Chicago. But not all, as we’ll see in a moment. Also this week, Biogen and Eisai reported good news about an Alzheimer’s drug, but with plenty of caveats. Axovant Sciences, which hit the skids last year because of a massive Alzheimer’s … Continue reading “Bio Roundup: Wrapping ASCO, Dreaming IPO, Rebooting Axovant & More”
Structural Snags $2.5M Investment to Fund Growth and Augment Platform
Structural, an employee-data management startup based in Indianapolis and the Twin Cities, today announced that it has raised $2.5 million in an equity investment round, with backing from High Alpha, Revolution’s Rise of the Rest Seed Fund, Matchstick Ventures, the Syndicate Fund, and Great North Labs. The 15-person company has raised just under $5 million … Continue reading “Structural Snags $2.5M Investment to Fund Growth and Augment Platform”
ASCO Wrap: Cancer Combos, Precision Meds, Stock Movers & More
The American Society of Clinical Oncology annual meeting, the world’s largest cancer conference, wraps up today in Chicago. Investors have dissected the data, picked winners and losers, and sent some biotech stocks soaring and others tumbling. In the days before ASCO, Xconomy previewed two major themes: the feverish and flawed race to develop cancer immunotherapy … Continue reading “ASCO Wrap: Cancer Combos, Precision Meds, Stock Movers & More”
Biotech’s Looming Talent Crisis: 5 Ways to Prepare for the Storm
Finding and keeping great talent has always been a limiting factor for building companies—and even more so in the life science industry, which requires highly specialized skills. As an executive recruiter focused solely on life sciences, I know firsthand the challenges of filling key executive roles, and I’m often the first to see signs of … Continue reading “Biotech’s Looming Talent Crisis: 5 Ways to Prepare for the Storm”
Xconomy’s Napa Summit Is June 14-15: Last Call for Invites
Just 10 days to go—but it’s not too late to request your invitation to Xconomy’s most unique and thought-provoking event of the year: our annual Napa Summit: The Xconomy Retreat on Technology, Jobs, and Growth. We only have a few spots left open, so get your wine on and request your invitation today. You will … Continue reading “Xconomy’s Napa Summit Is June 14-15: Last Call for Invites”
Price Check on Aisle 3: Retailers Turn to Robots to Manage Inventory
Inventory management is crucial to operating a successful retail operation. And as hard as it may be to believe, retailers “don’t really know what’s on the shelves,” says Sarjoun Skaff, founder and CTO of Bossa Nova Robotics. A combination of the sheer number of products a retailer like Walmart has on offer and the pace … Continue reading “Price Check on Aisle 3: Retailers Turn to Robots to Manage Inventory”
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Eli Lilly won regulatory approval for its rheumatoid arthritis drug Friday, nearly 14 months after the FDA rejected the once-daily pill due to safety concerns. But the approval comes with limitations that will likely hamper Lilly’s ambitions to turn the drug into a blockbuster seller. The regulatory nod covers only the lower of the two … Continue reading “Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning”
Drug Price Watchdog ICER Deems Amgen Migraine Drug “Cost-Effective”
As Amgen approached an FDA decision last month for its migraine-prevention treatment, concern mounted that the drug would come at premium. In setting a price thousands of dollars less than expected, Amgen has won over one of the pharmaceutical industry’s fiercest drug price critics. The non-profit Institute for Clinical and Economic Review (ICER) assessed the … Continue reading “Drug Price Watchdog ICER Deems Amgen Migraine Drug “Cost-Effective””
Hc1 Snags $7M Series B, Partners with Appriss on Opioid Dashboard
Hc1.com, the Indianapolis startup focused on healthcare relationship management and data analytics, recently scored $7 million in new capital to expand its presence in the market and drive further adoption of its products, including the company’s software dashboard for analyzing opioid use. The Series B round was led by Health Cloud Capital with participation from … Continue reading “Hc1 Snags $7M Series B, Partners with Appriss on Opioid Dashboard”
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
For the next five days, the oncology community’s attention will focus on Chicago. The Windy City is the home for the American Society of Clinical Oncology’s annual meeting, and it kicks off today. Many ASCO attendees will zero in on potential cancer drug combinations. They’re seen as the key to expanding the reach of caner … Continue reading “Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More”
Drugs OK’d To Hit Tumor Genes Still a Basket of One. Are More Coming?
[Corrected 6/4/18, 1:53 a.m. ET. See below.] One year ago, the FDA made biomedical history. A cancer drug, pembrolizumab (Keytruda), was approved to treat tumors with a specific genetic fingerprint regardless of their location in the body. It was the first tissue-agnostic approval of a cancer drug, and it was a big shift for the … Continue reading “Drugs OK’d To Hit Tumor Genes Still a Basket of One. Are More Coming?”
IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down
One year ago, on the eve of the yearly American Society of Clinical Oncology conference, a new class of drugs called IDO inhibitors seemed poised to become the next big thing in cancer care. They were a top choice to combine with the powerful but limited immunotherapies that have emerged this decade to fight many … Continue reading “IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down”
Smart-Kitchen Startups Give Cooks Digital Help Via Internet of Things
When it comes to connected homes, the hottest spot is located in your kitchen. The Internet of Things, artificial intelligence, and related technologies are being used to connect ovens, refrigerators, and other kitchen appliances to the Web. Feeling unsure about cooking that fish dish? Smart ovens can more accurately calibrate temperatures to avoid over-cooking. There’s … Continue reading “Smart-Kitchen Startups Give Cooks Digital Help Via Internet of Things”
Bio Roundup: Brii Does China, Hemophilia Updates, Right to Try & More
Sometimes disruption comes in waves. Since the 1990s, hemophilia patients have had to inject themselves with drugs a few times a week to prevent dangerous internal bleeding. That could soon change. One drug already approved, from Roche, may only need to be taken once a month by hemophilia A patients. Another experimental therapy from Alnylam … Continue reading “Bio Roundup: Brii Does China, Hemophilia Updates, Right to Try & More”
Request Your Invite for Our Napa Summit, June 14-15
In two and a half weeks, Xconomy will host our seventh annual Napa Summit: The Xconomy Retreat on Technology, Jobs, and Growth. In the heart of California’s wine country, it is our most exclusive, intimate, and unique conference. There are only a few tickets left—so request your invitation today to join fellow exemplary executives, innovators, … Continue reading “Request Your Invite for Our Napa Summit, June 14-15”
Biotech IPOs Roll On as Kiniksa, Scholar Rock Get $227M Combined
The IPO window remains wide open for biotechs. Two more, Kiniksa Pharmaceuticals and Scholar Rock, make their Wall Street debuts this morning having raised $227 million combined in their IPOs last night. Kiniksa exceeded its funding goals. The Lexington, MA, company sold 1.44 million more shares than it projected, or 8.44 million total, at $18 … Continue reading “Biotech IPOs Roll On as Kiniksa, Scholar Rock Get $227M Combined”
IU Spinout Vascugen Turns to Stem Cells for Blood Vessel Repair
Vascular-degenerative diseases such as critical limb ischemia are on the rise in the United States, but the millions of people affected by these disorders worldwide have limited treatment options and no cures. An regenerative medicine startup spun out of Indiana University called Vascugen is seeking to change that. Indianapolis-based Vascugen has licensed technology developed at … Continue reading “IU Spinout Vascugen Turns to Stem Cells for Blood Vessel Repair”
Fixing the Clinical Trial Bottleneck by Making Patients a Priority
The world of medicine and drug development has transformed dramatically over the past 50 years. Today, we have biologic medicines, genomic sequencing technologies, and digital health tools that help patients become more engaged in their care. But one part of the equation hasn’t seen very much change at all: clinical trials. Clinical trials are a … Continue reading “Fixing the Clinical Trial Bottleneck by Making Patients a Priority”
6 Simple Steps to Avoid Becoming a Cybercrime Statistic in 2018
We can all agree that 2017 was a brutal year for cybersecurity. Verizon’s Data Breach Investigation Report identified passwords as the root cause of more than 81 percent of breaches in 2016 – an 18 percent increase from the previous year. And, it’s a safe guess that this year, the percentage will grow. At last … Continue reading “6 Simple Steps to Avoid Becoming a Cybercrime Statistic in 2018”
Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout
There’s nothing abstract about a 20 percent jump in a company’s stock price. But yeah, that happened to Loxo Oncology when it released data previews for its American Society for Clinical Oncology presentations; the meeting starts in two weeks in Chicago. Wednesday was ASCO abstract day, and we’ll round up the headliners below, all with … Continue reading “Bio Roundup: ASCO Abstracts, Migraine Drug Prices & “Blueprint” Fallout”
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
[Updated 5/18/18, 8:38 a.m. See below.] An Amgen migraine drug developed to head off pain before it starts has won FDA approval, the first for a new class of preventive drug candidates for the condition. The Amgen (NASDAQ: [[ticker:AMGN]]) drug, erenumab (Aimovig), is a subcutaneous injection given once a month. The drug blocks the receptor … Continue reading “Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines”
Arevo Adds $12.5M to Expand 3D Printing into Manufacturing
[Updated 5/17/18, 9:45 am. See below.] Silicon Valley company Arevo, which competes with a growing number of rivals to transform 3D printing into a tool for mass manufacturing, announced today it raised $12.5 million in a Series B financing round. Arevo’s technology mix—which combines automated printing equipment with Web-based software and customized raw materials—exemplifies the … Continue reading “Arevo Adds $12.5M to Expand 3D Printing into Manufacturing”
Amgen Migraine Decision Looms, Maybe the Next Drug Price Fight, Too
For some migraine sufferers, bright lights or loud sounds are enough to touch off an attack. For others, stress sparks the onset of pain. Bright lights, loud sounds, stress: Migraine triggers vary from one patient to another. But a common element is the abundance of a pain-inducing protein in the blood. During a migraine attack, … Continue reading “Amgen Migraine Decision Looms, Maybe the Next Drug Price Fight, Too”
The Revolution in Inflammation Drug Development
Chronic autoimmune and inflammatory diseases are painful and often lifelong conditions. I know this both as a scientist and a father, as my son, Jeremy, was diagnosed 12 years ago with Crohn’s disease, one type of inflammatory bowel disease (IBD). According to the National Institutes of Health, there are more than 80 autoimmune diseases affecting … Continue reading “The Revolution in Inflammation Drug Development”
Arch’s Bob Nelsen on Big Biotech and Why Pharma Should Be Very Afraid
Arch Venture Partners co-founder and managing director Bob Nelsen is widely regarded as one of the most astute and successful life science investors and company builders in the game. The list of his portfolio company wins (if you think of raising money, going public, or being acquired as a win, which he doesn’t necessarily, read … Continue reading “Arch’s Bob Nelsen on Big Biotech and Why Pharma Should Be Very Afraid”
Powderkeg on a Mission to Unite, Grow Mid-American Tech Ecosystems
The East and West coasts have historically been the center of tech startup activity in the United States. . However, there is growing interest in innovation hubs in the middle of the country, especially as the high cost of coastal living is ever more prohibitive to many young entrepreneurs. One such effort to cultivate Midwestern … Continue reading “Powderkeg on a Mission to Unite, Grow Mid-American Tech Ecosystems”
Eli Lilly Bolsters Cancer Drug Pipeline with $110M Deal for AurKa
Eli Lilly is pulling out its checkbook again to acquire another cancer drug developer, this time inking a deal for early-stage company AurKa Pharma. Under the agreement announced Monday, Indianapolis-based Lilly (NYSE: [[ticker:LLY]]) will pay $110 million up front for AurKa. If the AurKa drug hits regulatory and commercialization milestones, AurKa shareholders could gain up … Continue reading “Eli Lilly Bolsters Cancer Drug Pipeline with $110M Deal for AurKa”
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
[Editor’s note: Corie Lok co-authored this report.] In a much anticipated speech at the White House this afternoon, President Trump unveiled a long-awaited plan meant to cut the cost of prescription drugs in the U.S. The administration’s “American Patients First” plan, released via a speech and an accompanying 38-page “blueprint” document, laid out some relatively … Continue reading “Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details”
“Unseen Is Unsold:” VR & Analytics Study What and Why Shoppers Buy
Humans are great about saying a lot of things. We’re not that good about actually following through. See: New Year’s diet resolutions or election polls. That tendency affects retailers as well. Big stores and brands spend millions in market research to figure out what shoppers want and then model production and creative teams to create those … Continue reading ““Unseen Is Unsold:” VR & Analytics Study What and Why Shoppers Buy”